Seres Therapeutics reported a net loss from continuing operations of $19.9 million for Q2 2025, a significant improvement from the $26.2 million loss in the same period last year. The company is actively seeking partnerships and other funding structures to advance its SER-155 program, which aims to prevent bloodstream infections. Cash and cash equivalents stood at $45.4 million as of June 30, 2025, with an additional $25 million received from Nestlé Health Science in July 2025, extending the cash runway into Q1 2026.

Seres Therapeutics reported a net income of $32.7 million for the first quarter of 2025, a significant improvement from a net loss of $32.9 million in the same period last year, primarily driven by a $50.0 million installment payment from Nestlé. The company also made significant progress in advancing SER-155, including plans to submit a Phase 2 study protocol to the FDA.

Seres Therapeutics' Q4 2024 revenue was classified under discontinued operations due to the sale of its VOWST business. The company reported a net loss of $15.7 million, a significant improvement from the $34.7 million loss in Q4 2023. Operating expenses decreased as the company streamlined its focus on SER-155. Cash and cash equivalents stood at $30.8 million, with additional funding expected from Nestlé in mid-2025.

Seres Therapeutics reported a net loss from continuing operations of $51 million for the third quarter of 2024. The company's financial position was strengthened by the VOWST sale, and they anticipate funding operations into Q4 2025.

Seres Therapeutics reported a net loss of $32.9 million for the second quarter of 2024. The company's VOWST asset sale is expected to provide a $175 million cash infusion, which will be used to retire debt and advance the company's pipeline.

Seres Therapeutics reported VOWST net sales of $10.1 million in Q1 2024, with approximately 1,411 patient enrollment forms received and approximately 1,083 new patient starts. The company's net loss for the quarter was $40.1 million, as compared to a net loss of $71.2 million for the same period in 2023.

Seres Therapeutics reported VOWST net sales of $10.4 million for the fourth quarter of 2023. The company's net loss for the quarter was $41.2 million, as compared to a net loss of $68.8 million for the same period in 2022.